Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
000250
vs
KOSPI 200
Over the past 12 months, Sam Chun Dang Pharm Co Ltd has underperformed KOSPI 200, delivering a return of -29% compared to KOSPI 200's +37% growth.
Stocks Performance
000250 vs KOSPI 200
Performance Gap
000250 vs KOSPI 200
Create a free account · No card needed
Performance By Year
000250 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Sam Chun Dang Pharm Co Ltd
Glance View
Sam Chun Dang Pharm Co Ltd is a South Korean pharmaceutical company that develops, manufactures, and sells prescription medicines and over-the-counter drugs. Its product lineup includes hospital and clinic medicines as well as consumer health products, with a strong focus on medicines used in treatment areas such as eye care and other common therapies. The company sells these products to hospitals, clinics, pharmacies, and other drug distributors. The company makes money mainly by producing medicines under its own brands and supplying them through domestic and overseas pharmaceutical channels. Like many drugmakers, it earns revenue when healthcare providers, pharmacies, or distributors buy its finished products, and it may also benefit from contract manufacturing and export sales. Its role is that of a middle-stage manufacturer: it takes pharmaceutical ingredients, turns them into finished dosage forms, and gets them to the medical market. What sets the business apart is its focus on specialized drug manufacturing rather than broad consumer branding. That means its value comes from regulatory know-how, product quality, and the ability to make reliable medicines that doctors, pharmacies, and partners can trust. For investors, this is a classic healthcare manufacturing business whose success depends on product approvals, manufacturing standards, and steady demand for medicines.
Create a free account · No card needed